• Intranasal Sumatriptan in Pediatric ED Migraine Care

  2026-09-04

  A single-center retrospective study evaluated an emergency department migraine pathway that placed intranasal sumatriptan early in treatment for patients aged 6 to 21 years. The pathway was associated with substantial improvement in documented pain scores, while intravenous access correlated with longer stays and higher charges, supporting further prospective evaluation of nonintravenous first-line care.

• Bifendate (DDB): Dose, Lipids, and Liver Models

  2026-09-04

  Bifendate (DDB) is a multifaceted hepatoprotection agent whose effects depend strongly on dose, exposure, and experimental context. This evidence-driven guide explains how to interpret its paradoxical lipid findings and design more reliable liver and autophagy studies.

• Adipose-Neural Axis in Cardiac Arrhythmia

  2026-09-03

  Fan et al. developed a stem cell-based coculture model showing how epicardial adipose tissue can influence cardiac electrical instability through a leptin–sympathetic neuron–NPY pathway. Their findings identify NPY/Y1R signaling, the Na+/Ca2+ exchanger, and CaMKII as mechanistic links between adipose tissue and arrhythmogenesis, while patient data support clinical relevance in atrial fibrillation.

• H2S Deficiency and ER Stress in Diabetic Cardiomyopathy

  2026-09-03

  The reference study identifies reduced endogenous hydrogen sulfide production as a mechanistic component of lipotoxic myocardial injury in diabetic cardiomyopathy and connects this deficit with endoplasmic reticulum stress. Its combination of patient samples, diabetic rats, and palmitate-treated cardiomyocytes provides a useful framework for evaluating H2S-centered disease mechanisms and rescue strategies.

• Exosomal Egr2 and the RNF8/DAPK1 Axis in Stroke

  2026-09-02

  A 2025 Experimental Brain Research study identifies BMSC-derived exosomal Egr2 as a protective regulator of OGD/R-induced neuronal injury. Its mechanistic model links exosomal Egr2 to RNF8 promoter activation, RNF8-dependent DAPK1 ubiquitination, and improved neuronal survival, while also illustrating how Co-IP can test protein relationships within a defined injury pathway.

• Reparixin in CXCR1/2 Signaling Workflows

  2026-09-02

  Reparixin provides a practical pharmacological test of CXCL8–CXCR1/2 signaling in neutrophil migration, tissue-injury, and tumor-microenvironment studies. This workflow connects receptor blockade with the 2026 MRSA extracellular-vesicle study while clearly separating validated findings from proposed extensions.

• Axonal CO2 Opens Paranodal Connexin32 Hemichannels

  2026-09-01

  Butler and colleagues identify axon-derived CO2 as an activity-dependent signal that opens Connexin32 hemichannels in Schwann cell paranodes. Using isolated mouse sciatic nerve, fluorescence imaging, pharmacology, molecular perturbation, and computational interpretation, the study links neuronal energy demand to glial modulation of conduction and provides a mechanistic framework relevant to Cx32-associated neuropathy.

• Ertapenem Sodium Salt in Resistance Assays

  2026-09-01

  Ertapenem sodium salt supports reproducible MIC testing, genotype-to-phenotype studies, and mechanistic antibiotic resistance research. This workflow connects compound handling with carbapenemase localization, plasmid transmission, and bacterial growth phenotypes without treating an in vitro result as a clinical decision.

• Hepatic sEH–Nrf2 Signaling in Osteoporosis

  2026-08-31

  The reference study identifies a liver–bone mechanism in which hepatic soluble epoxide hydrolase reshapes circulating 14,15-EET and 14,15-DHET, inflammatory signaling, and Nrf2-dependent osteoclastogenesis. By combining clinical samples, an ovariectomy-induced mouse model, liver-specific perturbation, osteoclast cultures, and transcriptomics, the work provides a mechanistic framework for studying redox imbalance in osteoporosis.

• Concanamycin A: Reliable V-ATPase Assays

  2026-08-30

  Learn how Concanamycin A, SKU A8633, can improve the interpretation and reproducibility of cell viability, apoptosis, and invasion experiments by selectively perturbing V-ATPase-dependent acidification. This scenario-based guide connects dosing, solvent handling, orthogonal readouts, and vendor selection to practical cancer biology research workflows.

• Streptozotocin: From β-Cell Injury to PDN Assays

  2026-08-29

  Streptozotocin is more than an experimental diabetes inducer: it is a model-design tool for separating β-cell injury, metabolic dysfunction, and painful diabetic neuropathy. This guide connects STZ exposure decisions with the TBK1–microglia pyroptosis pathway and practical assay selection.

• Ovalbumin mRNA as a Translational Testbed

  2026-08-29

  Ovalbumin mRNA provides a controlled model for separating payload biology from delivery-system effects. This thought-leadership guide explains how Cap 1 architecture, lipid nanoparticle design, and rigorous workflow control can strengthen immune response, gene expression, and vaccine development research.

• MLN8237 (Alisertib): From Mitosis to Immunity

  2026-08-28

  Explore how MLN8237 (Alisertib) combines highly selective Aurora A inhibition with a practical framework for studying mitosis, apoptosis, tumor biology, and trained immunity. This guide translates recent mechanistic findings into better assay design and interpretation.

• Nullscript: HDAC Inhibitor Workflow Guide

  2026-08-28

  Nullscript is a transcriptional-facilitation-inactive histone deacetylase inhibitor for separating HDAC-dependent biology from reporter-driven effects. This guide translates its cardiac evidence and the latest placental nanoplastic findings into practical assay workflows, controls, and troubleshooting strategies.

• Cyclopamine: From Hh Inhibition to Assay Design

  2026-08-27

  Cyclopamine is a Hedgehog signaling inhibitor with applications spanning oncogenic pathway analysis, APOC1-linked papillary thyroid carcinoma research, and developmental biology. This guide translates recent evidence into a practical framework for choosing models, controls, endpoints, and treatment conditions.

456 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page